Galmed Pharmaceuticals Ltd (GLMD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.48 (+2.05%), Market cap $0.00B, 52-week low–high $0.47 ~ $2.33.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methi
Financial statements, price targets, institutional (13F) holdings and related news for Galmed Pharmaceuticals Ltd are updated in real time on BlackAll Trade.
Galmed Pharmaceuticals Ltd trades at $3.48 (+2.05%). Real-time quotes and charts are available on BlackAll Trade.
Galmed Pharmaceuticals Ltd has a market cap of about $0.00B.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first